It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

The results of gene therapy for hemophilia B contrast with those of factor replacement therapies, where lifelong infusions ...

Huntington’s disease is a rare genetic disorder affecting movement, memory, and mood. Here’s what we know—and what’s ahead.

The antibody-based drug Andembry is the first to target factor XIIa, a protein responsible for swelling in people with this ...

With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.

Encouraged by the results of her most recent bone density scan, columnist G Shellye Horowitz pauses to celebrate the small ...